Taking on gamma delta T cells, bluebird pays $16M for TC BioPharm’s tumor invading tech platform – Endpoints News
Endpoints News |
Taking on gamma delta T cells, bluebird pays $16M for TC BioPharm's tumor invading tech platform
Endpoints News Gene therapy pioneer bluebird bio is teaming up with Scotland's TC BioPharm to get its hands on an experimental program involving an emerging immunotherapy platform: CAR-engineered gamma delta T cells. As part of the deal, bluebird $BLUE is paying TC … bluebird bio (BLUE) Reports Strategic Collaboration with TC BioPharm to Research and Develop Gamma Delta CAR T … Life sciences group TC BioPharm secures $16m US tie-up to develop new cancer treatments TC BioPharm teams up with bluebird bio to develop gamma delta CAR Ts |
